PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 89 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2022. The put-call ratio across all filers is 1.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $323,184 | -15.6% | 122,892 | +13.3% | 0.01% | -20.0% |
| Q2 2023 | $382,801 | +23.8% | 108,448 | +8.4% | 0.02% | +15.4% |
| Q1 2023 | $309,204 | -17.2% | 100,072 | +13.3% | 0.01% | -31.6% |
| Q4 2022 | $373,602 | +91.6% | 88,322 | +7.4% | 0.02% | +90.0% |
| Q3 2022 | $195,000 | -6.7% | 82,247 | +12.0% | 0.01% | -9.1% |
| Q2 2022 | $209,000 | +21.5% | 73,424 | +23.0% | 0.01% | +57.1% |
| Q1 2022 | $172,000 | +56.4% | 59,680 | +65.6% | 0.01% | +40.0% |
| Q4 2021 | $110,000 | -55.6% | 36,032 | +1.9% | 0.01% | -58.3% |
| Q3 2021 | $248,000 | +5.1% | 35,360 | +37.3% | 0.01% | 0.0% |
| Q2 2021 | $236,000 | +11.3% | 25,745 | +18.3% | 0.01% | -7.7% |
| Q1 2021 | $212,000 | +9.8% | 21,768 | +15.6% | 0.01% | 0.0% |
| Q4 2020 | $193,000 | +52.0% | 18,828 | +54.5% | 0.01% | +18.2% |
| Q2 2020 | $127,000 | – | 12,186 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |